Subverting toll-like receptor signaling by bacterial pathogens

Frontiers in Immunology

Volumn 6, Issue DEC, 2015, Pages

  McGuire, Victoria A ^a   Arthur, J Simon C ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Bacterial effector; Bacterial pathogen; MAPK; NF B; Signaling; TLR; Virulence

Indexed keywords

ACYLTRANSFERASE; DEUBIQUITINASE; MITOGEN ACTIVATED PROTEIN KINASE; PATTERN RECOGNITION RECEPTOR; PHOSPHOTHREONINE; PHOSPHOTRANSFERASE; PROTEINASE; TOLL LIKE RECEPTOR; UBIQUITIN PROTEIN LIGASE E3;

IMMUNE RESPONSE; INNATE IMMUNITY; NONHUMAN; SALMONELLA ENTERICA SEROVAR TYPHIMURIUM; SHORT SURVEY; SIGNAL TRANSDUCTION; VIRULENCE;

EID: 84954235561     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00607     Document Type: Short Survey

References (66)

1. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on toll-like receptors. Nat Immunol (2010) 11(5):373-84. doi: 10.1038/ni.1863.
2. Coll RC, O'Neill LA. New insights into the regulation of signalling by toll-like receptors and nod-like receptors. J Innate Immun (2010) 2(5):406-21. doi:10.1159/000315469.
3. Arthur JSC, Ley SC. Mitogen-activated protein kinases in innate immunity. Nat Rev Immunol (2013) 13(9):679-92. doi:10.1038/nri3495.
4. Cohen P. The TLR and IL-1 signalling network at a glance. J Cell Sci (2014) 127(Pt 11):2383-90. doi:10.1242/jcs.149831.
5. Odendall C, Rolhion N, Förster A, Poh J, Lamont DJ, Liu M, et al. The Salmonella kinase SteC targets the MAP kinase MEK to regulate the host actin cytoskeleton. Cell Host Microbe (2012) 12(5):657-68. doi:10.1016/j.chom.2012.09.011.
6. Bruno VM, Hannemann S, Lara-Tejero M, Flavell RA, Kleinstein SH, Galán JE. Salmonella Typhimurium type III secretion effectors stimulate innate immune responses in cultured epithelial cells. PLoS Pathog (2009) 5(8):e1000538. doi:10.1371/journal.ppat.1000538.
7. Ge J, Xu H, Li T, Zhou Y, Zhang Z, Li S, et al. A Legionella type IV effector activates the NF-kappaB pathway by phosphorylating the IkappaB family of inhibitors. Proc Natl Acad Sci U S A (2009) 106(33):13725-30. doi:10.1073/pnas.0907200106.
8. Newman RM, Salunkhe P, Godzik A, Reed JC. Identification and characterization of a novel bacterial virulence factor that shares homology with mammalian toll/interleukin-1 receptor family proteins. Infect Immun (2006) 74(1):594-601. doi:10.1128/IAI.74.1.594-601.2006.
9. Askarian F, van Sorge NM, Sangvik M, Beasley FC, Henriksen JR, Sollid JU, et al. A Staphylococcus aureus TIR domain protein virulence factor blocks TLR2-mediated NF-κB signaling. J Innate Immun (2014) 6(4):485-98. doi:10.1159/000357618.
10. Cirl C, Wieser A, Yadav M, Duerr S, Schubert S, Fischer H, et al. Subversion of toll-like receptor signaling by a unique family of bacterial toll/interleukin-1 receptor domain-containing proteins. Nat Med (2008) 14(4):399-406. doi:10.1038/nm1734.
11. Rana RR, Simpson P, Zhang M, Jennions M, Ukegbu C, Spear AM, et al. Yersinia pestis TIR-domain protein forms dimers that interact with the human adaptor protein MyD88. Microb Pathog (2011) 51(3):89-95. doi:10.1016/j.micpath.2011.05.004.
12. Salcedo SP, Marchesini MI, Degos C, Terwagne M, Von Bargen K, Lepidi H, et al. BtpB, a novel Brucella TIR-containing effector protein with immune modulatory functions. Front Cell Infect Microbiol (2013) 3(July):28. doi:10.3389/fcimb.2013.00028.
13. Radhakrishnan GK, Yu Q, Harms JS, Splitter GA. Brucella TIR domain-containing protein mimics properties of the toll-like receptor adaptor protein TIRAP. J Biol Chem (2009) 284(15):9892-8. doi:10.1074/jbc.M805458200.
14. Sengupta D, Koblansky A, Gaines J, Brown T, West AP, Zhang D, et al. Subversion of innate immune responses by Brucella through the targeted degradation of the TLR signaling adapter. J Immunol (2010) 184(2):956-64. doi:10.4049/jimmunol.0902008.
15. Duesbery NS, Webb CP, Leppla SH, Gordon VM, Klimpel KR, Copeland TD, et al. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science (1998) 280(5364):734-7. doi:10.1126/science.280.5364.734.
16. Vitale G, Bernardi L, Napolitani G, Mock M, Montecucco C. Susceptibility of mitogen-activated protein kinase kinase family members to proteolysis by anthrax lethal factor. J Biochem (2000) 745:739-45. doi:10.1042/bj3520739.
17. Baruch K, Gur-Arie L, Nadler C, Koby S, Yerushalmi G, Ben-Neriah Y, et al. Metalloprotease type III effectors that specifically cleave JNK and NF-κB. EMBO J (2011) 30(1):221-31. doi:10.1038/emboj.2010.297.
18. Yen H, Ooka T, Iguchi A, Hayashi T, Sugimoto N, Tobe T. NleC, a type III secretion protease, compromises NF-kB activation by targeting p65/rela. PLoS Pathog (2010) 6(12):e1001231. doi:10.1371/journal.ppat.1001231.
19. Mühlen S, Ruchaud-Sparagano MH, Kenny B. Proteasome-independent degradation of canonical NFκB complex components by the NleC protein of pathogenic Escherichia coli. J Biol Chem (2011) 286(7):5100-7. doi:10.1074/jbc.M110.172254.
20. Pearson JS, Riedmaier P, Marchès O, Frankel G, Hartland EL. A type III effector protease NleC from enteropathogenic Escherichia coli targets NF-κB for degradation. Mol Microbiol (2011) 80(1):219-30. doi:10.1111/j.1365-2958.2011.07568.x.
21. Lad SP, Yang G, Scott DA, Wang G, Nair P, Mathison J, et al. Chlamydial CT441 Is a PDZ domain-containing tail-specific protease that interferes with the NF-κB pathway of immune response. J Bacteriol (2007) 189(18):6619-25. doi:10.1128/JB.00429-07.
22. Lad SP, Li J, da Silva Correia J, Pan Q, Gadwal S et al. Cleavage of p65/RelA of the NF- B pathway by Chlamydia. Proc Natl Acad Sci U S A (2007) 104(8):2933-8. doi:10.1073/pnas.0608393104.
23. Christian J, Vier J, Paschen SA, Häcker G. Cleavage of the NF-κB family protein p65/RelA by the chlamydial protease-like activity factor (CPAF) impairs proinflammatory signaling in cells infected with chlamydiae. J Biol Chem (2010) 285(53):41320-7. doi:10.1074/jbc.M110.152280.
24. Trosky JE, Mukherjee S, Burdette DL, Roberts M, McCarter L, Siegel RM, et al. Inhibition of MAPK signaling pathways by VopA from Vibrio parahaemolyticus. J Biol Chem (2004) 279(50):51953-7. doi:10.1074/jbc.M407001200.
25. Trosky JE, Li Y, Mukherjee S, Keitany G, Ball H, Orth K. VopA inhibits ATP binding by acetylating the catalytic loop of MAPK kinases. J Biol Chem (2007) 282(47):34299-305. doi:10.1074/jbc.M706970200.
26. Jones RM, Wu H, Wentworth C, Luo L, Collier-Hyams L, Neish AS. Salmonella AvrA coordinates suppression of host immune and apoptotic defenses via JNK pathway blockade. Cell Host Microbe (2008) 3(4):233-44. doi:10.1016/j.chom.2008.02.016.
27. Du F, Galán JE. Selective inhibition of type III secretion activated signaling by the Salmonella effector AvrA. PLoS Pathog (2009) 5(9):1-12. doi:10.1371/journal.ppat.1000595.
28. Orth K, Palmer LE, Bao ZQ, Stewart S, Rudolph AE, Bliska JB, et al. Inhibition of the mitogen-activated protein kinase kinase superfamily by a Yersinia effector. Science (1999) 285(5435):1920-3. doi:10.1126/science.285.5435.1920.
29. Mukherjee S, Keitany G, Li Y, Wang Y, Ball HL, Goldsmith EJ, et al. Yersinia YopJ acetylates and inhibits kinase activation by blocking phosphorylation. Science (2006) 312:1211-4. doi:10.1126/science.1126867.
30. Mittal R, Peak-Chew S-Y, McMahon HT. Acetylation of MEK2 and I kappa B kinase (IKK) activation loop residues by YopJ inhibits signaling. Proc Natl Acad Sci U S A (2006) 103(49):18574-9. doi:10.1073/pnas.0608995103.
31. Paquette N, Conlon J, Sweet C, Rus F, Wilson L, Pereira A, et al. Serine/threonine acetylation of TGF-β-activated kinase (TAK1) by Yersinia pestis YopJ inhibits innate immune signaling. Proc Natl Acad Sci U S A (2012) 109(31):12710-5. doi:10.1073/pnas.1008203109.
32. Haase R, Richter K, Pfaffinger G, Courtois G, Ruckdeschel K. Yersinia outer protein P suppresses TGF-β-activated kinase-1 activity to impair innate immune signaling in Yersinia enterocolitica-infected cells. J Immunol (2005) 175(12):8209-17. doi:10.4049/jimmunol.175.12.8209.
33. Thiefes A, Wolf A, Doerrie A, Grassl GA, Matsumoto K, Autenrieth I, et al. The Yersinia enterocolitica effector YopP inhibits host cell signalling by inactivating the protein kinase TAK1 in the IL-1 signalling pathway. EMBO Rep (2006) 7(8):838-44. doi:10.1038/sj.embor.7400754.
34. Meinzer U, Barreau F, Esmiol-Welterlin S, Jung C, Villard C, Léger T, et al. Yersinia pseudotuberculosis effector YopJ subverts the Nod2/RICK/TAK1 pathway and activates caspase-1 to induce intestinal barrier dysfunction. Cell Host Microbe (2012) 11(4):337-51. doi:10.1016/j.chom.2012.02.009.
35. Kim KH, An DR, Song J, Yoon JY, Kim HS, Yoon HJ, et al. Mycobacterium tuberculosis Eis protein initiates suppression of host immune responses by acetylation of DUSP16/MKP-7. Proc Natl Acad Sci U S A (2012) 109(20):7729-34. doi:10.1073/pnas.1120251109.
36. Cao W, Bao C, Padalko E, Lowenstein CJ. Acetylation of mitogen-activated protein kinase phosphatase-1 inhibits Toll-like receptor signaling. J Exp Med (2008) 205(6):1491-503. doi:10.1084/jem.20071728.
37. Li H, Xu H, Zhou Y, Zhang J, Long C, Li S, et al. The phosphothreonine lyase activity of a bacterial type III effector family. Science (2007) 315(5814):1000-3. doi:10.1126/science.1138960.
38. Mazurkiewicz P, Thomas J, Thompson JA, Liu M, Arbibe L, Sansonetti P, et al. SpvC is a Salmonella effector with phosphothreonine lyase activity on host mitogen-activated protein kinases. Mol Microbiol (2008) 67(6):1371-83. doi:10.1111/j.1365-2958.2008.06134.x.
39. Brennan DF, Barford D. Eliminylation: a post-translational modification catalyzed by phosphothreonine lyases. Trends Biochem Sci (2009) 34(3):108-14. doi:10.1016/j.tibs.2008.11.005.
40. Arbibe L, Kim DW, Batsche E, Pedron T, Mateescu B, Muchardt C, et al. An injected bacterial effector targets chromatin access for transcription factor NF-kappaB to alter transcription of host genes involved in immune responses. Nat Immunol (2007) 8(1):47-56. doi:10.1038/ni1423.
41. Kramer RW, Slagowski NL, Eze NA, Giddings KS, Morrison MF, Siggers KA, et al. Yeast functional genomic screens lead to identification of a role for a bacterial effector in innate immunity regulation. PLoS Pathog (2007) 3(2):179-90. doi:10.1371/journal.ppat.0030021.
42. Reiterer V, Grossniklaus L, Tschon T, Kasper CA, Sorg I, Arrieumerlou C. Shigella flexneri type III secreted effector OspF reveals new crosstalks of proinflammatory signaling pathways during bacterial infection. Cell Signal (2011) 23(7):1188-96. doi:10.1016/j.cellsig.2011.03.006.
43. Kim DW, Lenzen G, Page AL, Legrain P, Sansonetti PJ, Parsot C. The Shigella flexneri effector OspG interferes with innate immune responses by targeting ubiquitin-conjugating enzymes. Proc Natl Acad Sci U S A (2005) 102(39):14046-51. doi:10.1073/pnas.0504466102.
44. Zhou Y, Dong N, Hu L, Shao F. The Shigella type three secretion system effector OspG directly and specifically binds to host ubiquitin for activation. PLoS One (2013) 8(2). doi:10.1371/journal.pone.0057558.
45. Pruneda JN, Smith FD, Daurie A, Swaney DL, Villén J, Scott JD, et al. E2~Ub conjugates regulate the kinase activity of Shigella effector OspG during pathogenesis. EMBO J (2014) 33(5):437-49. doi:10.1002/embj.201386386.
46. Royan SV, Jones RM, Koutsouris A, Roxas JL, Falzari K, Weflen AW, Kim A, et al. Enteropathogenic E. coli non-LEE encoded effectors NleH1 and NleH2 attenuate NF-κB activation. Mol Microbiol (2010) 78(5):1232-45. doi:10.1111/j.1365-2958.2010.07400.x.
47. Gao X, Wan F, Mateo K, Callegari E, Wang D, Deng W, et al. Bacterial effector binding to ribosomal protein S3 subverts NF-κB function. PLoS Pathog (2009) 5(12):e1000708. doi:10.1371/journal.ppat.1000708.
48. Rohde JR, Breitkreutz A, Chenal A, Sansonetti PJ, Parsot C. Type III secretion effectors of the IpaH family are E3 ubiquitin ligases. Cell Host Microbe (2007) 1(1):77-83. doi:10.1016/j.chom.2007.02.002.
49. Hicks SW, Galán JE. Hijacking the host ubiquitin pathway: structural strategies of bacterial E3 ubiquitin ligases. Curr Opin Microbiol (2010) 13(1):41-6. doi:10.1016/j.mib.2009.11.008.
50. Ashida H, Kim M, Schmidt-Supprian M, Ma A, Ogawa M, Sasakawa C. A bacterial E3 ubiquitin ligase IpaH9.8 targets NEMO/IKKgamma to dampen the host NF-kappaB-mediated inflammatory response. Nat Cell Biol (2010) 12(1):66-73. doi:10.1038/ncb2006.
51. Wang F, Jiang Z, Li Y, He X, Zhao J, Yang X, et al. Shigella flexneri T3SS effector IpaH4.5 modulates the host inflammatory response via interaction with NF-κB p65 protein. Cell Microbiol (2013) 15(3):474-85. doi:10.1111/cmi.12052.
52. Ashida H, Nakano H, Sasakawa C. Shigella IpaH0722 E3 ubiquitin Ligase effector targets TRAF2 to Inhibit PKC-NF-κB activity in invaded epithelial cells. PLoS Pathog (2013) 9(6):1-15. doi:10.1371/journal.ppat.1003409.
53. Suzuki S, Mimuro H, Kim M, Ogawa M, Ashida H, Toyotome T, et al. Shigella IpaH7.8 E3 ubiquitin ligase targets glomulin and activates inflammasomes to demolish macrophages. Proc Natl Acad Sci U S A (2014) 111(40):E4254-63. doi:10.1073/pnas.1324021111.
54. Collier-Hyams LS, Zeng H, Sun J, Tomlinson AD, Bao ZQ, Chen H, et al. Cutting edge: Salmonella AvrA effector inhibits the key proinflammatory, anti-apoptotic NF- B pathway. J Immunol (2002) 169(6):2846-50. doi:10.4049/jimmunol.169.6.2846.
55. Ye Z, Petrof EO, Boone D, Claud EC, Sun J. Salmonella effector AvrA regulation of colonic epithelial cell inflammation by deubiquitination. Am J Pathol (2007) 171(3):882-92. doi:10.2353/ajpath.2007.070220.
56. Le Negrate G, Krieg A, Faustin B, Loeffler M, Godzik A, Krajewski S, et al. ChlaDub1 of chlamydia trachomatis suppresses NF-kappaB activation and inhibits IkappaBalpha ubiquitination and degradation. Cell Microbiol (2008) 10(9):1879-92. doi:10.1111/j.1462-5822.2008.01178.x.
57. Le Negrate G, Faustin B, Welsh K, Loeffler M, Krajewska M, Hasegawa P, et al. Salmonella secreted factor L deubiquitinase of Salmonella typhimurium Inhibits NF-κB, suppresses IκBa ubiquitination. The J Immunol (2008) 180:5045-56. doi:10.4049/jimmunol.180.7.5045.
58. Shanks J. Burtnick MN, Brett PJ, Waag DM, Spurgers KB, Ribot WJ, et al., Burkholderia mallei tssM encodes a putative deubiquitinase that is secreted and expressed inside infected RAW 264.7 murine macrophagest. Infect Immun (2009) 77(4):1636-48. doi:10.1128/IAI.01339-08.
59. Misaghi S, Balsara ZR, Catic A, Spooner E, Ploegh HL, Starnbach MN. Chlamydia trachomatis-derived deubiquitinating enzymes in mammalian cells during infection. Mol Microbiol (2006) 61(1):142-50. doi:10.1111/j.1365-2958.2006.05199.x.
60. Tan KS, Chen Y, Lim YC, Tan GG, Liu Y, Lim YT, et al. Suppression of host innate immune response by Burkholderia pseudomallei through the virulence factor TssM. J Immunol (2010) 184(9):5160-71. doi:10.4049/jimmunol.0902663.
61. Wang J, Li BX, Ge PP, Li J, Wang Q, Gao GF, et al. Mycobacterium tuberculosis suppresses innate immunity by coopting the host ubiquitin system. Nat Immunol (2015) 16(3). doi:10.1038/ni.3096.
62. Sanada T, Kim M, Mimuro H, Suzuki M, Ogawa M, Oyama A, et al. The Shigella flexneri effector OspI deamidates UBC13 to dampen the inflammatory response. Nature (2012) 483(7391):623-6. doi:10.1038/nature10894.
63. Zhang L, Ding X, Cui J, Xu H, Chen J, Gong YN, et al. Cysteine methylation disrupts ubiquitin-chain sensing in NF-κB activation. Nature (2011) 481(7380):204-8. doi:10.1038/nature10690.
64. Nadler C, Baruch K, Kobi S, Mills E, Haviv G, Farago M, et al. The type III secretion effector NleE inhibits NF-κB activation. PLoS Pathog (2010) 6(1):403-4. doi:10.1371/journal.ppat.1000743.
65. Newton HJ, Pearson JS, Badea L, Kelly M, Lucas M, Holloway G, et al. The type III effectors NieE and NleB from enteropathogenic E. coli and Ospz from shigella block nuclear translocation of NF-κB p65. PLoS Pathog (2010) 6(5):1-16. doi:10.1371/journal.ppat.1000898.
66. Spear AM, Rana RR, Jenner DC, Flick-Smith HC, Oyston PC, Simpson P, et al. A Toll/interleukin (IL)-1 receptor domain protein from Yersinia pestis interacts with mammalian IL-1/Toll-like receptor pathways but does not play a central role in the virulence of Y. pestis in a mouse model of bubonic plague. Microbiology (2012) 158(6):1593-606. doi:10.1099/mic.0.055012-0.